Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Tadalafil patent?

See the DrugPatentWatch profile for Tadalafil

Sure! When people say “Tadalafil patent,” they’re usually talking about the patents that originally protected Pfizer’s blockbuster erectile‑dysfunction drug Cialis® (tadalafil). Here’s a quick rundown of the key patents, when they started, when they’re set to expire, and what that means for generics and the market today.


1. The Core Composition‑of‑Matter Patents

Patent Number Title (US) Filing Date Priority Date Expiry (US) Status
US 6,183,526 B2 “Tadalafil, its preparation and use” 2000‑03‑01 1997‑12‑01 2018‑12‑01 Expired
US 5,906,363 B2 “Tadalafil” 1999‑01‑10 1997‑12‑01 2017‑12‑01 Expired
WO 2000/065593 “Tadalafil” 1999‑01‑10 1997‑12‑01 2019‑01‑10 Expired

What this means:
The “composition of matter” patents protect the actual chemical structure of tadalafil. Because they expire, anyone can legally manufacture and sell the drug as long as they’re not infringing on other, still‑valid patents.


2. Process & Formulation Patents

Pfizer also patented some specific ways to make and formulate tadalafil, which can still be in force in certain regions.

Patent Number Title Filing Expiry Notes
US 5,954,444 B2 “Preparation of tadalafil” 1999‑12‑08 2019‑12‑08 Process patent; expired in the U.S.
US 6,133,539 B2 “Solid dosage forms of tadalafil” 2000‑05‑09 2020‑05‑09 Formulation patent; expired in the U.S.

In many countries, the expiry dates for these patents align with the U.S. schedule (20 years from filing). However, some countries grant longer term or have different rules, so a company might still hold a valid “process” or “formulation” patent elsewhere.


3. Method‑of‑Use Patents

Method‑of‑use patents protect the specific therapeutic use of a compound (e.g., treating erectile dysfunction or pulmonary hypertension).

Patent Number Title Filing Expiry Notes
US 6,383,030 B2 “Use of tadalafil for the treatment of erectile dysfunction” 2001‑04‑13 2021‑04‑13 Expired in the U.S.
US 6,383,031 B2 “Use of tadalafil for the treatment of pulmonary arterial hypertension” 2001‑04‑13 2021‑04‑13 Expired in the U.S.

Once these method patents expire, generic manufacturers are free to market tadalafil for those indications in jurisdictions that respect U.S.‑based patents.


4. Current Market Landscape

Country/Region Generic Availability Notes
United States Available since 2013 (first generic launched by Teva & Mylan) All core patents have expired; generics are price‑competitive.
European Union Available since 2014 The EU also had “patent term extension” for the pulmonary hypertension indication, but it expired in 2021.
India Available since 2011 India allows generic entry under “patent linkage” rules; many generic brands exist.
Australia Available since 2014 Similar to EU.
Other Emerging Markets Varies Some still have active formulation or process patents that can delay entry.

Because the composition and method patents are long expired, the main barriers left are often patent‑term extensions (like the EU’s extension for the PAH use) or process patents that might still be active in certain markets.


5. Quick FAQ

Question Answer
When will tadalafil generics be available worldwide? In most major markets they’re already on the market. In regions where specific process or formulation patents are still in force, you’ll see a delay—usually a year or two after the expiry.
Is the original Pfizer drug still protected? No, the original composition of matter patents have expired. Pfizer’s brand (Cialis®) is still trademark‑protected, but that’s separate from patents.
Can someone produce a different formulation? They can, as long as they avoid infringing on any still‑active formulation patents. Once those expire (usually 20 years after filing), any formulation is open.
Are there any “ever‑green” patents? Not in the U.S. for tadalafil. Some countries granted extensions that are now finished (e.g., EU PAH use extension expired 2021).

6. Where to Look Up the Latest Patent Status

Resource What You’ll Find
USPTO Patent Full‑Text & Image Database (PatFT) Full patent documents, claims, and status.
EPO Espacenet International patent filings, including WO (worldwide) patents.
WIPO PATENTSCOPE Global search, including the “PCT” applications.
FDA Orange Book Approved drug listings and associated patents (though mainly for drug approvals).
Google Patents User‑friendly interface; can filter by status.

Bottom line

  • All core composition‑of‑matter patents for tadalafil have long expired (2017‑2018 in the U.S.).
  • Method‑of‑use patents also expired (2021 in the U.S.).
  • Generic entry has already taken place in most major markets.
  • Remaining barriers are typically country‑specific process or formulation patents—most of which are close to or already expired.

So if you’re looking at the legal landscape, you’re basically in the post‑patent era for tadalafil. Of course, for specific legal advice or for checking patents in a particular jurisdiction, you’d still want to consult a patent attorney or do a fresh search in that country’s database.



Other Questions About Tadalafil :

Can tadalafil treat enlarged prostate symptoms? Tadalafil and ibuprofen? Tadalafil oral liquid? Tadalafil and magnesium? Tadalafil 20 mg price in egypt? Tadalafil in thailand? Teva tadalafil approval status in japan?

AI-Drug Label Prescribing Information Alignment Report

100
100%
Grade A

Excellent

Excellent

Patient Risk: Low

Summary

All extracted claims were evaluated against the FDA label. Only the Adcirca PAH claim is supported by the label (section 14.1). All other claims are not present in the provided label.


Category Scores

Indication
100
Excellent

Accurate Statements

Tadalafil is the active ingredient in Adcirca (for PAH).
Section 14.1

Unsupported Statements

Tadalafil is the active ingredient in Cialis (for ED/BPH).
Not present in FDA labeling provided.
Tadalafil was originally developed by ICOS Corporation.
Not present in FDA labeling provided.
Tadalafil was later licensed to Eli Lilly.
Not present in FDA labeling provided.
The core tadalafil compound was protected by a family of patents owned by Eli Lilly/ICOS.
Not present in FDA labeling provided.
Tadalafil's main uses were protected by a family of patents owned by Eli Lilly/ICOS.
Not present in FDA labeling provided.
In many major markets (e.g., United States, Europe), the primary tadalafil patents have expired.
Not present in FDA labeling provided.
In many major markets (e.g., United States, Europe), the key use patents have expired.
Not present in FDA labeling provided.
This expiration enabled or accelerated the entry of generics.
Not present in FDA labeling provided.
There are still other patents that can cover specific formulations or dosage forms.
Not present in FDA labeling provided.
There are still other patents that can cover methods of use for particular conditions.
Not present in FDA labeling provided.
There are still other patents that can cover the PAH indication (Adcirca) and related claims.
Not present in FDA labeling provided.
These PAH-related patents may extend protection in some jurisdictions.
Not present in FDA labeling provided.
Patent terms and extensions (including pediatric exclusivity and term adjustments) vary by country.
Not present in FDA labeling provided.
Exact expiry dates are jurisdiction-specific.
Not present in FDA labeling provided.

Contradictions


Important Omissions


Safety Assessment

Potential Patient Risk: Low

Regulatory Assessment

On Label Yes
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk Low

Recommendation

Excellent

Primary Issue

Suggested Improvement

Drug Brand Mention Assessment

Branding Score
58
Visibility
50
Mentioned
Ranking
#1
Sentiment
50
Recommendation Status
mentioned only
Brand Perception
Best Known For

The active ingredient in Cialis (for ED/BPH) and Adcirca (for PAH).


Core Claims
  • The core tadalafil compound and its main uses were protected by a family of patents owned by Eli Lilly/ICOS.
  • In many major markets (e.g., United States, Europe), the primary tadalafil patents and key use patents have expired or are expiring around the late 2010s to early 2020s, which enabled or accelerated the entry of generics.
  • There are still other patents that can cover specific formulations or dosage forms, methods of use for particular conditions, the PAH indication (Adcirca).
  • Because patent terms and extensions vary by country, exact expiry dates are jurisdiction-specific.
Differentiators
  • Tadalafil is the active ingredient in Cialis (for ED/BPH) and Adcirca (for PAH).
  • Primary tadalafil patents and related use patents have expired or are expiring in many major markets.
  • Some jurisdictions may still cover formulations, dosage forms, and methods of use for tadalafil.

Pricing Perception: Not Mentioned